Embarking on the Next Stage in iPS Cell Research: Clinical Applications

In a groundbreaking new venture, Kyoto University’s Center for iPS Cell Research and Application (CiRA), directed by Professor Shinya Yamanaka, and Takeda Pharmaceutical Company have formed a 10-year joint program to develop clinical applications of iPS cell technology. Professor Yamanaka believes this program, T-CiRA, will be an engine for the development of breakthrough treatments in many areas of drug discovery and regenerative medicine. We see a bright future in the collaboration and Takeda has committed the resources to ensure that the partnership has every chance of delivering innovative treatments. With a strong expectation of near-future healthcare breakthroughs, T-CiRA presents excellent opportunities for researchers interested in clinical application involving iPS cell technology.

Seeking associates for challenging research at T-CiRA

Initial areas of research include heart failure, diabetes mellitus, neuro-psychiatric disorders and cancer immunotherapy. This is challenging work on the leading-edge of biomedical research supported by Takeda, Japan’s largest pharmaceutical company. For information, please visit:

http://www.cira.kyoto-u.ac.jp/e/t-cira.html
http://takedajobs.com/